Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Leukemia

NCT04100187 is registered in ClinicalTrials.gov with Kecellitics Biotech Company Ltd as lead sponsor.

NCT NCT04100187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04100187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Leukemia
Lead sponsor
Kecellitics Biotech Company Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
February 1, 2023
Completion date
August 1, 2024
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia